Jennifer Riley
Chief Strategy Officer · Avalo Therapeutics, Inc.
- 2026
- Aug 12, 2026
- 4
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Jennifer Riley files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Christopher Ryan Sullivan - $3.72M in AVTX purchases and sales in the last 12 months
- Mittie Doyle - $2.98M in AVTX purchases and sales in the last 12 months
- Paul Varki - $1.51M in AVTX purchases and sales in the last 12 months
- Jonathan Goldman - $163K in AVTX purchases and sales in the last 12 months
- Mitchell Chan - $72K in AVTX purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Jennifer Riley?
Jennifer Riley is a corporate insider, tracked as Chief Strategy Officer of Avalo Therapeutics, Inc. (AVTX). InsiderAlpha holds 4 primary Form 4 filings for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Jennifer Riley submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Jennifer Riley been buying or selling stock?
Recorded transactions: 0 open-market purchases and 1 open-market sale ($52K) across all tracked filings.
